Skip to Content

Marrone Bio Innovations, Inc.

Merger

  • Date:
  • 3/17/2022
  • Company Name:
  • Marrone Bio Innovations, Inc.
  • Stock Symbol:
  • MBII
  • Company Name - Buyer:
  • Bioceres Crop Solutions Corp.
  • Stock Symbol - Buyer:
  • BIOX
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 3/16/2022

Case Finder

Locate any case using the tools below.

NEW YORK, March 17, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“MBI”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Bioceres Crop Solutions Corp. (NASDAQ: BIOX).

On March 16, 2022, MBI announced that it had entered into an agreement to merge with Bioceres in a deal valued at approximately $236 million.  Pursuant to the merger agreement, MBI stockholders will receive ordinary shares of Bioceres at a fixed ratio of 0.088.  The deal is scheduled to close in the third quarter of 2022.

Bragar Eagel & Squire is concerned that MBI’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for MBI’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Marrone Bio Innovations. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: